golidocitinib (DZD4205) / Dizal Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Enrollment open, Combination therapy:  Go-CHOP as the Frontline Therapy for PTCL (clinicaltrials.gov) -  Sep 1, 2023   
    P2,  N=45, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Poteligeo (mogamulizumab) / Kyowa Kirin, golidocitinib (DZD4205) / Dizal Pharma
    Journal:  Rare Lymphomas: Getting "a Bit Ahead". (Pubmed Central) -  Aug 7, 2023   
    According to data from the phase III IELSG37 trial, consolidation radiotherapy is unnecessary for patients with primary mediastinal B-cell lymphoma who respond completely to standard immunochemotherapy. Two other studies of peripheral T-cell lymphomas and adult T-cell leukemia/lymphoma, respectively, point to golidocitinib, an investigational JAK1 inhibitor, and mogamulizumab, which targets CCR4, as potential new treatment options.
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    New P2 trial, Combination therapy:  Go-CHOP as the Frontline Therapy for PTCL (clinicaltrials.gov) -  Jul 27, 2023   
    P2,  N=45, Not yet recruiting, 
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Trial completion date, Trial primary completion date, Monotherapy:  Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) (clinicaltrials.gov) -  Jun 22, 2023   
    P2,  N=160, Recruiting, 
    Two other studies of peripheral T-cell lymphomas and adult T-cell leukemia/lymphoma, respectively, point to golidocitinib, an investigational JAK1 inhibitor, and mogamulizumab, which targets CCR4, as potential new treatment options. Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Jan 2023 --> Sep 2023
  • ||||||||||  Novel Targeted Agents in T-Cell Lymphoma (LEVEL 3, GENERAL ASSEMBLY) -  Jun 21, 2023 - Abstract #SOHO2023SOHO_195;    
    The exception is represented by brentuximab vedotin, which has an indication in relapsed or refractory ALCL, however with much more disappointing results in other PTCL subtypes...Four agents currently under evaluation in clinical trials are reviewed in this paper: the phosphatidylinositol-3 kinase (PI3K) inhibitors duvelisib and linperlisib; the Janus kinase (JAK) 1 inhibitor golidocitinib (DZD4205); the enhancer of zeste homologs 1 and 2 (EZH1/ EZH2) inhibitor valemetostat...Conclusion Translational research, from the bench to the bed, provides better knowledge of the mechanisms of the disease and suggests novel targets to hit. Newer agents currently under evaluation in clinical trials, including the novel PI3K inhibitors, JAK1 inhibitors and EZH1/EZH2 inhibitors, may provide a step forward to the treatment of relapsed and refractory PTCL.
  • ||||||||||  Journal:  Peripheral T-cell lymphomas. (Pubmed Central) -  Jun 13, 2023   
    Do we require an autologous stem cell transplantation in all patients? Is there room for improvement in the setting of relapsed and refractory disease?
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Trial completion, Trial completion date:  Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine (clinicaltrials.gov) -  Feb 1, 2023   
    P1,  N=32, Completed, 
    https://clinicaltrials.gov/ct2/show/NCT03728023?term=NCT03728023&draw=2&rank=1, identifier (NCT03728023); http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml, identifier (CTR20191011). Recruiting --> Completed | Trial completion date: Apr 2023 --> Oct 2022
  • ||||||||||  Next Questions: T-Cell Lymphomas () -  Sep 22, 2022 - Abstract #SOHO2022SOHO_394;    
    The exception is represented by brentuximab vedotin, which has an indication in relapsed or refractory anaplastic large cell lymphoma, however with much more disappointing results in other PTCL subtypes...This abstract reviews the available data about 3 classes of agents now under evaluation in active clinical trials: the phosphatidylinositol-3 kinase (PI3K) inhibitors duvelisib and linperlisib; the Janus kinase (JAK) 1 inhibitor golidocitinib (DZD4205); the enhancer of zeste homologs 1 and 2 (EZH1/EZH2) inhibitor valemetostat...Grade 3-4 neutropenia, anemia and thrombocytopenia represented the most frequent adverse events correlated with valemetostat. Conclusion New drugs currently under evaluation in clinical trials, including the novel PI3K inhibitors, JAK1 inhibitors and EZH1/EZH2 inhibitors, may be one of the answers to the burning question: “How can we treat patients with relapsed or refractory PTCL?”
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Trial completion date, Trial primary completion date, Monotherapy:  Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) (clinicaltrials.gov) -  Jan 28, 2022   
    P2,  N=160, Recruiting, 
    Golidocitinib shows good safety and promising anti-tumor efficacy in r/r PTCL, indicating its potential as a therapeutic option for this unmet medical need. Trial completion date: Nov 2022 --> Jul 2023 | Trial primary completion date: May 2022 --> Jan 2023
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Phase classification, Monotherapy:  Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) (clinicaltrials.gov) -  Nov 30, 2020   
    P2,  N=160, Recruiting, 
    Early results from this ongoing phase I/II study suggest good tolerability and promising anti-tumor efficacy of DZD4205 in r/r PTCL, indicating its potential as a therapeutic option for this unmet medical need. Phase classification: P1/2 --> P2
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Enrollment change, Trial completion date, Trial primary completion date, Monotherapy:  Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) (clinicaltrials.gov) -  Sep 1, 2020   
    P1/2,  N=160, Recruiting, 
    Compound 21 displayed an enhanced antitumor activity in combination with approved EGFR inhibitor, osimertinib, in a preclinical non-small cell lung cancer (NSCLC) xenograft NCI-H1975 model. N=100 --> 160 | Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Dec 2020 --> Feb 2022
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Trial completion, Trial completion date, Trial primary completion date:  JACKPOT2: A Study of AZD4205 in Healthy Adult Subjects (clinicaltrials.gov) -  Feb 7, 2020   
    P1,  N=66, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Aug 2019 | Trial primary completion date: Jan 2020 --> Aug 2019
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Enrollment closed, Trial primary completion date:  JACKPOT2: A Study of AZD4205 in Healthy Adult Subjects (clinicaltrials.gov) -  Sep 29, 2019   
    P1,  N=66, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2019 --> Dec 2019
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma
    Enrollment open:  JACKPOT2: A Study of AZD4205 in Healthy Adult Subjects (clinicaltrials.gov) -  Apr 25, 2019   
    P1,  N=66, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2019 --> Dec 2019 Not yet recruiting --> Recruiting